A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
about
Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC.Nivolumab for the treatment of bladder cancer.Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis.PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomyThe tissue distribution and significance of B7-H4 in laryngeal carcinoma.Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.Immunotherapy of cancer: targeting cancer during active disease or during dormancy?Atezolizumab in urothelial bladder carcinoma.Neurologic complications of immune checkpoint inhibitors.An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer.Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer.How to assess and improve health-related quality of life in bladder cancer patients.Regulation of Immune Cell Functions by Metabolic Reprogramming.RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells.Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies.Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma.Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China.Safety and efficacy of durvalumab (MEDI4736) in various solid tumors.A Festschrift in Honor of Edward M. Messing, MD, FACSImmune checkpoint inhibitors as a real hope in advanced urothelial carcinoma
P2860
Q33819820-527EA202-676B-418D-AF65-61A12253C396Q33912075-CA62C2DE-4C76-4BD3-98A4-A88F7675FA10Q38700564-87948A07-C183-42A1-9472-64CE50741CB6Q39454030-5925507F-6118-4223-A728-1FBF9F0A26D9Q41709065-07553E29-2400-48A6-B135-7B9B331103BFQ42366515-0610DE8E-ADFD-485D-845D-59CF9B25C45AQ47102186-EFBB68F3-62F8-4B3B-8C1B-972B56B890ECQ47157402-B06C3198-0225-4A7D-BC86-AC00C2421122Q47261543-2D316072-0557-4501-BB4D-54BD3686609DQ47291286-247BBA69-4717-4FC8-B5F1-1F44061E68A7Q47729557-B08A7C8A-BA72-4130-89DE-16FD0C0A0834Q47841004-023519ED-0CC9-417D-BDD4-FEA309F9B3BBQ48248403-EBD7CEEA-8D0B-4A18-991C-6C85809DADAFQ49791794-FEE9E419-F780-46FD-96E1-AFF295DCB945Q50064748-9BEE720A-A1F2-4DA7-A51C-6FF97CCF5564Q52671150-DAFDD327-1236-44D7-AE65-D664575FA873Q54942723-D64F94E4-F3E2-4380-8B77-F665908F77B1Q54952659-709EC451-8C16-4091-8239-D0C13877F94FQ54979788-7E14BC83-8FE6-4D70-9745-8646D65E96E8Q55081994-CD5FD313-E6BD-468E-8D58-21590D62CE51Q55282839-FCD3D2AA-2AAB-4F97-B242-31C51D7CE80AQ55400961-0318B76B-C558-4974-BEA4-EE153A096A95Q55716958-1BF17E9C-6120-46EA-94EE-ED828584B01CQ58691149-77E1664F-B976-485D-AE98-7CA9E5B3F662Q59137334-13336735-C9C6-403F-B0F7-0163EE68D358
P2860
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A review on the evolution of P ...... der cancer: The future is now.
@en
type
label
A review on the evolution of P ...... der cancer: The future is now.
@en
prefLabel
A review on the evolution of P ...... der cancer: The future is now.
@en
P2093
P1476
A review on the evolution of P ...... der cancer: The future is now.
@en
P2093
Joaquin Bellmunt
Nicholas J Vogelzang
Thomas Powles
P356
10.1016/J.CTRV.2017.01.007
P577
2017-02-02T00:00:00Z